Entheon Biomedical Corp.: Entheon Biomedical to be Included in First North American Psychedelic ETF Vancouver, British Columbia--(Newsfile Corp. - January 22, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) ( "Entheon" or the "Company"), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind. The new ETF is expected to start trading January 26, 2021 under the symbol "PYSK" on the NEO exchange. The Psychedelic ETF invests in North American publicly-listed companies focused on psychedelic medicines, providing diversified exposure to the psychedelics industry, and is designed to reflect the evolution of the industry in a timely fashion. The underlying index of the Psychedelic ETF is the North American Psychedelics Stock Index and measures performance of its constituent companies.